Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Maharashtra launches a groundbreaking 28-day TB treatment for HIV patients aiming to reduce mortality and improve healthcare ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Fostemsavir plus optimized background therapy was associated with improvements in immune biomarkers among HTE patients with MDR HIV infection.

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.